Gilead Reuters

Gilead Sciences, Inc. (NASDAQ: GILD) shares are volatile in Tuesday's post-market session after the company beat Wall Street revenue and earnings estimates handily. Perhaps more importantly to some investors, Gilead reported that sales for its Hep C drugs, Harvoni and Sovaldi, totaled $4.89...